Delivery Order SPE2DB24D9238-SPE2DB24FDQGJ

Award Date 5/23/24
Potential Completion Date 6/14/24
Potential Value $1.5K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Park Ridge, IL 60068, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
The U.S. Defense Logistics Agency (DLA) awarded a firm fixed-price delivery order contract to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $4,633.32 contract is for the delivery of Lucentis 0.5 mg/0.05 ml, a prescription medication, to support the medical supply needs of military health facilities. This delivery order is part of DMS Pharmaceutical Group's larger $499,999,999 indefinite delivery contract (IDC) with the...
The U.S. Defense Logistics Agency (DLA) awarded a firm fixed-price delivery order contract to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $3,088.88 contract will provide LUCENTIS 0.5 MG/0.05 ML SYRING 0.05ML medical supplies to support the recurring pharmaceutical needs of military health facilities under the DLA's Medical Supply Chain division. This delivery order is part of a larger $499,999,999 indefinite delivery...
The U.S. Defense Logistics Agency (DLA) awarded a firm fixed-price delivery order (SPE2DX24F5ZZU) valued at $11,583.30 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler, to provide Lucentis 0.5 mg/0.05 ml syringes. This delivery order is part of a larger indefinite delivery contract (SPE2DB), valued up to $499,999,999, that DMS Pharmaceutical Group holds with the DLA to supply a comprehensive range of pharmaceutical products to support the recurring medical...
This firm-fixed-price delivery order, valued at $3,035.76, was awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The order is part of a larger indefinite delivery contract (IDC) valued at up to $499,999,999 that DMS Pharmaceutical Group holds with the DLA under the SPE2DB program. This single-award IDC allows the DLA to issue delivery orders for a comprehensive range of...
The U.S. Defense Logistics Agency (DLA) awarded a firm fixed-price delivery order contract worth $4,633.32 to DMS Pharmaceutical Group Inc., a woman-owned small business. The contract is for the delivery of Lucentis 0.5 mg/0.05 ml syringes, which are used to treat various medical conditions. The contract has an ultimate completion date of August 9, 2024 and does not have a set-aside designation. DMS Pharmaceutical Group is a key supplier in the federal pharmaceutical supply chain, providing a...
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business based in Park Ridge, Illinois. The $1,155.24 contract is for the supply of Lucentis 0.3 mg/0.05 ml syringes to fulfill the recurring pharmaceutical needs of military health facilities. DMS Pharmaceutical Group holds a single-award indefinite delivery contract (IDC) with the DLA under the SPE2DB program, valued at up to $499,999,999, which runs...
This is a delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract, valued at $3,861.10, is for the delivery of LUCENTIS 0.5 MG/0.05 ML SYRING 0.05ML, a pharmaceutical product. The contract is a firm fixed-price delivery order with a performance period through May 29, 2024. DMS Pharmaceutical Group Inc. holds a larger indefinite delivery contract (IDC) with the...
This federal contract award was issued by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $15,444.40 firm fixed-price delivery order contract is for the purchase of the drug Lucentis 0.5 mg/0.05 ml syringe. This award is part of a larger $499,999,999 indefinite delivery contract (IDC) held by DMS Pharmaceutical Group with the DLA under the SPE2DB program, which allows the DLA to issue...
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business based in Park Ridge, Illinois. The contract, valued at $1,544.44, is for the supply of the pharmaceutical product Lucentis 0.5 mg/0.05 ml syringe 0.05 ml. DMS Pharmaceutical Group holds a significant single-award indefinite delivery contract (IDC) with the DLA under the SPE2DB program, valued at up to $499,999,999, which runs through December...
This federal contract award was issued by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $1,544.44 firm fixed-price delivery order is for the supply of LUCENTIS 0.5 MG/0.05 ML syringes, with a completion date of October 8, 2024. DMS Pharmaceutical Group holds a significant indefinite delivery contract (IDC) with the DLA under the SPE2DB program, valued at up to $499,999,999, which runs...
  • SPE2DB24D9238
    Indefinite Delivery Contract
  • SPE2DB24D9238-SPE2DB24FDQGJ
    Delivery Order

The U.S. Defense Logistics Agency (DLA) awarded a firm fixed-price delivery order contract to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract, valued at $1,544.44, is for the delivery of Lucentis 0.5 mg/0.05 ml syringes to support the medical supply needs of military health facilities. This delivery order is part of a larger indefinite delivery contract (IDC) with DMS Pharmaceutical Group, valued up to $499,999,999, that allows the DLA to issue orders for a comprehensive range of pharmaceutical products to fulfill the recurring medical requirements of the Department of Defense (DoD) healthcare system. The contract does not have a set-aside designation.

Generated 8/22/24, 3:08 PM